When COVID-19 disrupted life sciences, solutions were needed in real-time. As the pandemic grew, so did the need to innovate. Workers met the challenges. They …
Just proving that an intervention has benefits is not always enough for it to be adopted into clinical practice. Yet in the past, pharma Medical …
The European Commission (EC) has authorised Celltrion’s COVID-19 monoclonal antibody (mAb) treatment Regkirona (regdanvimab, CT-P59), the company announced yesterday. The marketing authorisation allows for the …
Pfizer has signed a new deal with UN-backed organisation the Medicines Patent Pool (MPP) to increase access to its COVID-19 treatment for low- and middle-income …
The Joint Committee on Vaccination and Immunisation (JCVI) has updated its guidance and is now advising that all adults aged 40 to 49 should also …
Novavax has received the first emergency use authorisation (EUA) for its COVID-19 vaccine in Indonesia, with the company adding it is expecting further authorisations in …
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of …
COVID sufferers in the UK are now able to access a course of tablets from their GP to avoid the need for hospitalisation. AiPharma’s antiviral …
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achieved a statistically significant …
Private biopharmaceutical research, development, and commercialisation company, AiPharma, has announced a strategic alliance with biopharmaceutical company Appili Therapeutics Inc (Appili), to advance the global development …
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative
